-
1
-
-
0003964363
-
-
Atlanta: American Cancer Society, Inc
-
Cancer Facts & Figures 2013. Atlanta: American Cancer Society, Inc; 2013.
-
(2013)
Cancer Facts & Figures 2013.
-
-
-
2
-
-
8244254377
-
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
-
Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-13.
-
(1997)
J Clin Oncol.
, vol.15
, pp. 2403-2413
-
-
Burris III, H.A.1
Moore, M.J.2
Andersen, J.3
-
3
-
-
34249933404
-
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group
-
Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-6.
-
(2007)
J Clin Oncol.
, vol.25
, pp. 1960-1966
-
-
Moore, M.J.1
Goldstein, D.2
Hamm, J.3
-
4
-
-
79955921754
-
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer
-
Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817-25.
-
(2011)
N Engl J Med.
, vol.364
, pp. 1817-1825
-
-
Conroy, T.1
Desseigne, F.2
Ychou, M.3
-
5
-
-
84886741654
-
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine
-
Von Hoff D, Ervin T, Arena F, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691-1703.
-
(2013)
N Engl J Med.
, vol.369
, pp. 1691-1703
-
-
Von Hoff, D.1
Ervin, T.2
Arena, F.3
-
6
-
-
37549072095
-
-
National Comprehensive Cancer Network. Pancreatic adenocarcinoma, v.1.2013
-
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Pancreatic adenocarcinoma, v.1.2013.
-
NCCN clinical practice guidelines in oncology
-
-
-
7
-
-
68949114505
-
Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: A trial of the Eastern Cooperative Oncology Group
-
Poplin E, Feng Y, Berlin J, et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009;27:3778-85.
-
(2009)
J Clin Oncol.
, vol.27
, pp. 3778-3785
-
-
Poplin, E.1
Feng, Y.2
Berlin, J.3
-
8
-
-
73949135518
-
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer
-
Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009;27:5513-8.
-
(2009)
J Clin Oncol.
, vol.27
, pp. 5513-5518
-
-
Cunningham, D.1
Chau, I.2
Stocken, D.D.3
-
9
-
-
77950498286
-
Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: The GIP-1 study
-
Colucci G, Labianca R, Di Costanzo F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol. 2010;28:1645-51.
-
(2010)
J Clin Oncol.
, vol.28
, pp. 1645-1651
-
-
Colucci, G.1
Labianca, R.2
Di Costanzo, F.3
-
10
-
-
50849115450
-
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer: Definitive results of the 2000-01 FFCD/SFRO study
-
Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer: definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol. 2008;19:1592-9.
-
(2008)
Ann Oncol.
, vol.19
, pp. 1592-1599
-
-
Chauffert, B.1
Mornex, F.2
Bonnetain, F.3
-
11
-
-
33748297529
-
A multicenter phase III trial comparing irinotecan, gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer
-
Stathopoulos GP, Syrigos K, Aravantinos G, et al. A multicenter phase III trial comparing irinotecan, gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer. 2006;95:587-92.
-
(2006)
Br J Cancer.
, vol.95
, pp. 587-592
-
-
Stathopoulos, G.P.1
Syrigos, K.2
Aravantinos, G.3
-
12
-
-
27144530079
-
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer
-
Oettle H, Richards D, Ramanathan RK, et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol. 2005;16:1639-45.
-
(2005)
Ann Oncol.
, vol.16
, pp. 1639-1645
-
-
Oettle, H.1
Richards, D.2
Ramanathan, R.K.3
-
13
-
-
4644327989
-
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate
-
Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004;22:3776-83.
-
(2004)
J Clin Oncol.
, vol.22
, pp. 3776-3783
-
-
Rocha Lima, C.M.1
Green, M.R.2
Rotche, R.3
-
14
-
-
77955914277
-
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205
-
Philip PA, Benedetti J, Corless CL, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol. 2010;28:3605-10.
-
(2010)
J Clin Oncol.
, vol.28
, pp. 3605-3610
-
-
Philip, P.A.1
Benedetti, J.2
Corless, C.L.3
-
15
-
-
35348915953
-
Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value?
-
Miksad RA, Schnipper L, Goldstein M. Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value? J Clin Oncol. 2007;25:4506-7.
-
(2007)
J Clin Oncol.
, vol.25
, pp. 4506-4507
-
-
Miksad, R.A.1
Schnipper, L.2
Goldstein, M.3
-
16
-
-
36348999029
-
Is it cost effective to add erlotinib to gemcitabine in advanced pancreatic cancer?
-
[abstract 6048]
-
Grubbs B, Grusenmeyer PA, Petrelli NJ, et al. Is it cost effective to add erlotinib to gemcitabine in advanced pancreatic cancer? [abstract 6048] J Clin Oncol. 2006;24(suppl 18S):313.
-
(2006)
J Clin Oncol.
, vol.24
, Issue.SUPPL. 18S
, pp. 313
-
-
Grubbs, B.1
Grusenmeyer, P.A.2
Petrelli, N.J.3
-
17
-
-
84875993686
-
Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals
-
Miyabayashi K, Ijichi H, Mohri D, et al. Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals. Cancer Res. 2013;73:2221-34.
-
(2013)
Cancer Res.
, vol.73
, pp. 2221-2234
-
-
Miyabayashi, K.1
Ijichi, H.2
Mohri, D.3
-
18
-
-
0042284883
-
SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions
-
Sato N, Fukushima N, Maehara N, et al. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene. 2003;22:5021-30.
-
(2003)
Oncogene.
, vol.22
, pp. 5021-5030
-
-
Sato, N.1
Fukushima, N.2
Maehara, N.3
-
19
-
-
33846916208
-
Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma
-
Infante JR, Matsubayashi H, Sato N, et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol. 2007;25:319-25.
-
(2007)
J Clin Oncol.
, vol.25
, pp. 319-325
-
-
Infante, J.R.1
Matsubayashi, H.2
Sato, N.3
-
20
-
-
55949136282
-
SPARC in cancer biology: Its role in cancer progression and potential for therapy
-
Tai IT, Tang MJ. SPARC in cancer biology: its role in cancer progression and potential for therapy. Drug Resist Updat. 2008;11:231-46.
-
(2008)
Drug Resist Updat.
, vol.11
, pp. 231-246
-
-
Tai, I.T.1
Tang, M.J.2
-
21
-
-
33748459642
-
Single agent paclitaxel in the treatment of unresectable and/or metastatic pancreatic adenocarcinoma
-
Gebbia N, Gebbia V. Single agent paclitaxel in the treatment of unresectable and/or metastatic pancreatic adenocarcinoma. Eur J Cancer. 1996;32A:1822-3.
-
(1996)
Eur J Cancer.
, vol.32 A
, pp. 1822-1823
-
-
Gebbia, N.1
Gebbia, V.2
-
22
-
-
32944482677
-
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer
-
Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794-803.
-
(2005)
J Clin Oncol.
, vol.23
, pp. 7794-7803
-
-
Gradishar, W.J.1
Tjulandin, S.2
Davidson, N.3
-
23
-
-
0037499918
-
Neovascular targeting therapy: Paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy
-
Schmitt-Sody M, Strieth S, Krasnici S, et al. Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. Clin Cancer Res. 2003;9:2335-41.
-
(2003)
Clin Cancer Res.
, vol.9
, pp. 2335-2341
-
-
Schmitt-Sody, M.1
Strieth, S.2
Krasnici, S.3
-
24
-
-
2542559832
-
Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies
-
Kim T-Y, Kim D-W, Chung J-Y, et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res. 2004;10:3708-16.
-
(2004)
Clin Cancer Res.
, vol.10
, pp. 3708-3716
-
-
Kim, T.-Y.1
Kim, D.-W.2
Chung, J.-Y.3
-
25
-
-
0042284883
-
SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions
-
Sato N, Fukushima N, Maehara N, et al. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene. 2003;22:5021-30.
-
(2003)
Oncogene.
, vol.22
, pp. 5021-5030
-
-
Sato, N.1
Fukushima, N.2
Maehara, N.3
-
26
-
-
33644753906
-
Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel
-
Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 2006;12:1317-24.
-
(2006)
Clin Cancer Res.
, vol.12
, pp. 1317-1324
-
-
Desai, N.1
Trieu, V.2
Yao, Z.3
-
27
-
-
77952168147
-
Targeted delivery for breast cancer therapy: The history of nanoparticle-albumin-bound paclitaxel
-
Petrelli F, Borgonovo K, Barni S. Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel. Expert Opin Pharmacother. 2010;11:1413-32.
-
(2010)
Expert Opin Pharmacother.
, vol.11
, pp. 1413-1432
-
-
Petrelli, F.1
Borgonovo, K.2
Barni, S.3
-
28
-
-
84893420940
-
Approves a drug for late-stage pancreatic cancer
-
Sep 6. Available at
-
Pollack A. F.D.A. approves a drug for late-stage pancreatic cancer. New York Times. 2013 Sep 6. Available at: http://www.nytimes.com/2013/09/07/business/fda-approves-drug-for-late-stage-pancreatic-cancer.ht ml.
-
(2013)
New York Times.
-
-
Pollack, A.F.D.A.1
-
29
-
-
83355169753
-
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: A phase I/II trial
-
Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011;29:4548-54.
-
(2011)
J Clin Oncol.
, vol.29
, pp. 4548-4554
-
-
Von Hoff, D.D.1
Ramanathan, R.K.2
Borad, M.J.3
-
30
-
-
84863849090
-
Nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer
-
Frese KK, Neesse A, Cook N, et al. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov. 2012;2:260-9.
-
(2012)
Cancer Discov.
, vol.2
, pp. 260-269
-
-
Frese, K.K.1
Neesse, A.2
Cook, N.3
-
31
-
-
84875890529
-
Cost-effectiveness of systemic therapies for metastatic pancreatic cancer
-
Tam VC, Ko YJ, Mittmann N, et al. Cost-effectiveness of systemic therapies for metastatic pancreatic cancer. Curr Oncol. 2013;20:e90-e106.
-
(2013)
Curr Oncol.
, vol.20
-
-
Tam, V.C.1
Ko, Y.J.2
Mittmann, N.3
|